Evidence map›Paper›PMID 40838752›Full record

ArticleJournal of virology2025

Parallel evolution of the elite neutralizer phenotype in divergent HIV-1 clades.

Kathryn A Mesa, Sophia W Li, Jennie M Hutchinson, Sara O'Rourke, David L Alexander, Bin Yu, Xiaoying Shen, Terri Wrin, Christos J Petropoulos, Phillip W Berman and 1 more

Abstract read
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kathryn A MesaDepartment of Biomolecular Engineering, Baskin School of Engineering, University of California Santa Cruz, Santa Cruz, California, USA.ORCID 0000-0002-6521-534X
Sophia W LiDepartment of Biomolecular Engineering, Baskin School of Engineering, University of California Santa Cruz, Santa Cruz, California, USA.
Jennie M HutchinsonDepartment of Biomolecular Engineering, Baskin School of Engineering, University of California Santa Cruz, Santa Cruz, California, USA.
Sara O'RourkeDepartment of Biomolecular Engineering, Baskin School of Engineering, University of California Santa Cruz, Santa Cruz, California, USA.
David L AlexanderDepartment of Biomolecular Engineering, Baskin School of Engineering, University of California Santa Cruz, Santa Cruz, California, USA.
Bin YuDepartment of Biomolecular Engineering, Baskin School of Engineering, University of California Santa Cruz, Santa Cruz, California, USA.
Xiaoying ShenThe Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.ORCID 0000-0002-8387-3952
Terri WrinMonogram Biosciences, South San Francisco, California, USA.
Christos J PetropoulosMonogram Biosciences, South San Francisco, California, USA.
Phillip W BermanDepartment of Biomolecular Engineering, Baskin School of Engineering, University of California Santa Cruz, Santa Cruz, California, USA.
Grant H PogsonDepartment of Ecology & Evolutionary Biology, University of California Santa Cruz, Santa Cruz, California, USA.

Funding

Re-engineering gp120 to include glycan-dependent epitopesR01AI113893 · NIAID · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI BERMAN, PHILLIP WAYNE · 2014 to 2017
$4.2M
Enhanced Anti-HIV-1 Antibody Responses in African American Women Seropositive forR01DA036335 · NIDA · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI BERMAN, PHILLIP WAYNE · 2013 to 2017
$3.0M
NIAID NIH HHS HHSN272201800004CNIAID NIH HHS R01 AI113893NIDA NIH HHS R01 DA036335
6 · The paper itself

Abstract

The development of an effective vaccine against HIV-1 requires understanding how broadly neutralizing antibodies (bNAbs) evolve in natural viral infections. Here, we recovered 152 envelope sequences from two elite neutralizers (ENs) and five viral controllers and determined the neutralization sensitivity (IC

Indexed as

Biological EvolutionHIV-1HIV InfectionsAnimalsAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusEpitopesHIV AntibodiesHumansMolecular Docking SimulationPhylogenyPolymorphism, GeneticPolysaccharidesProtein Structure, TertiaryRabbitsSelection, GeneticAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusEpitopesHIV AntibodiesPolysaccharidesevolutionary biologyHIV-1

Identifiers

PMID40838752
PMCPMC12455966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.